Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253569677> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4253569677 endingPage "2397" @default.
- W4253569677 startingPage "2391" @default.
- W4253569677 abstract "BACKGROUND The International Prognostic Index (IPI) effectively separates aggressive lymphomas into four groups with significantly different responses to therapy and survival. The authors have applied the IPI to evaluate a series of patients with human immunodeficiency virus (HIV) related lymphoma, a disease for which treatment strategies are still controversial and prognostic indicators are therefore particularly important. METHODS Sixty-nine consecutive evaluable patients with HIV-related systemic non-Hodgkin lymphoma (NHL) diagnosed at a single Institution during a 10-year period were analyzed. Primary cerebral lymphoma was not considered. Forty-nine patients (71%) received aggressive combination chemotherapy (CT), 45 of whom were treated with the same program: cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, and methotrexate with lecuovorin and prednisone (ProMACE-CytaBOM). Univariate and multivariate methods were used for statistical analysis. End points were response to treatment in patients receiving aggressive CT and survival of treated patients and all patients. RESULTS According to age-adjusted IPI, 5 patients (7%) belonged to the low risk group, 12 (17%) to the low-intermediate risk group, 16 (23%) to the high-intermediate risk group, and 36 (52%) to the high risk group. Among the four groups with increasing IPI scores, the mean CD4 cell count at NHL diagnosis was 313, 230, 151, and 72/μL, respectively (P = 0.0085). The complete response (CR) rates were 100%, 88%, 50%, and 32% (P = 0.0001) and the median survival of all patients was >60, 17, 10.9, and 6.8 months (P = 0.0002) for patients with low, low-intermediate, high-intermediate, and high risk IPI scores, respectively. In multivariate analysis, among patients receiving aggressive CT, high risk IPI (P = 0.013) and systemic symptoms (P = 0.014) were the only parameters related to CR, and high risk IPI (P = 0.016) and achievement of CR (P < 0.001) were the only parameters related to survival. When all patients were considered, high risk IPI had significant prognostic value for overall survival (P = 0.01), as did age (P = 0.019) and achievement of CR (P < 0.001). CONCLUSIONS IPI was a reliable prognostic indicator in an unselected series of patients with HIV-related systemic NHL. The outcomes of patients without high risk IPI treated with aggressive CT were similar to those expected for HIV negative patients with lymphoma. However more than half of patients with HIV-related NHL had IPI high risk disease, and their outcomes were poor even after aggressive CT. The degree of immunodeficiency was related to increasing IPI score, suggesting that immunodeficiency may be an important factor contributing to the aggressive clinical presentation of lymphoma. Cancer 1999;86:2391–7. © 1999 American Cancer Society." @default.
- W4253569677 created "2022-05-12" @default.
- W4253569677 creator A5003638268 @default.
- W4253569677 creator A5020124946 @default.
- W4253569677 creator A5024845137 @default.
- W4253569677 creator A5024987917 @default.
- W4253569677 creator A5041635592 @default.
- W4253569677 creator A5068517502 @default.
- W4253569677 date "1999-12-01" @default.
- W4253569677 modified "2023-09-23" @default.
- W4253569677 title "The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus—related systemic non‐Hodgkin lymphoma" @default.
- W4253569677 doi "https://doi.org/10.1002/(sici)1097-0142(19991201)86:11<2391::aid-cncr29>3.3.co;2-s" @default.
- W4253569677 hasPublicationYear "1999" @default.
- W4253569677 type Work @default.
- W4253569677 citedByCount "0" @default.
- W4253569677 crossrefType "journal-article" @default.
- W4253569677 hasAuthorship W4253569677A5003638268 @default.
- W4253569677 hasAuthorship W4253569677A5020124946 @default.
- W4253569677 hasAuthorship W4253569677A5024845137 @default.
- W4253569677 hasAuthorship W4253569677A5024987917 @default.
- W4253569677 hasAuthorship W4253569677A5041635592 @default.
- W4253569677 hasAuthorship W4253569677A5068517502 @default.
- W4253569677 hasBestOaLocation W42535696771 @default.
- W4253569677 hasConcept C126322002 @default.
- W4253569677 hasConcept C141071460 @default.
- W4253569677 hasConcept C144301174 @default.
- W4253569677 hasConcept C2776694085 @default.
- W4253569677 hasConcept C2776755627 @default.
- W4253569677 hasConcept C2776907518 @default.
- W4253569677 hasConcept C2778041864 @default.
- W4253569677 hasConcept C2778119113 @default.
- W4253569677 hasConcept C2778476033 @default.
- W4253569677 hasConcept C2778476748 @default.
- W4253569677 hasConcept C2778720950 @default.
- W4253569677 hasConcept C2779338263 @default.
- W4253569677 hasConcept C2779429289 @default.
- W4253569677 hasConcept C38180746 @default.
- W4253569677 hasConcept C71924100 @default.
- W4253569677 hasConcept C90924648 @default.
- W4253569677 hasConceptScore W4253569677C126322002 @default.
- W4253569677 hasConceptScore W4253569677C141071460 @default.
- W4253569677 hasConceptScore W4253569677C144301174 @default.
- W4253569677 hasConceptScore W4253569677C2776694085 @default.
- W4253569677 hasConceptScore W4253569677C2776755627 @default.
- W4253569677 hasConceptScore W4253569677C2776907518 @default.
- W4253569677 hasConceptScore W4253569677C2778041864 @default.
- W4253569677 hasConceptScore W4253569677C2778119113 @default.
- W4253569677 hasConceptScore W4253569677C2778476033 @default.
- W4253569677 hasConceptScore W4253569677C2778476748 @default.
- W4253569677 hasConceptScore W4253569677C2778720950 @default.
- W4253569677 hasConceptScore W4253569677C2779338263 @default.
- W4253569677 hasConceptScore W4253569677C2779429289 @default.
- W4253569677 hasConceptScore W4253569677C38180746 @default.
- W4253569677 hasConceptScore W4253569677C71924100 @default.
- W4253569677 hasConceptScore W4253569677C90924648 @default.
- W4253569677 hasIssue "11" @default.
- W4253569677 hasLocation W42535696771 @default.
- W4253569677 hasOpenAccess W4253569677 @default.
- W4253569677 hasPrimaryLocation W42535696771 @default.
- W4253569677 hasRelatedWork W160156331 @default.
- W4253569677 hasRelatedWork W1966216463 @default.
- W4253569677 hasRelatedWork W1992716617 @default.
- W4253569677 hasRelatedWork W2068885458 @default.
- W4253569677 hasRelatedWork W2088845007 @default.
- W4253569677 hasRelatedWork W2092993480 @default.
- W4253569677 hasRelatedWork W2139211474 @default.
- W4253569677 hasRelatedWork W2178567417 @default.
- W4253569677 hasRelatedWork W2183352065 @default.
- W4253569677 hasRelatedWork W2427336549 @default.
- W4253569677 hasVolume "86" @default.
- W4253569677 isParatext "false" @default.
- W4253569677 isRetracted "false" @default.
- W4253569677 workType "article" @default.